Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OSE ImmunotherapeuticsORPOF 41 Days Sales Outstanding is 315.83 as of Dec. 2025, which is 1092% above its 10-year median of 26.50. GuruFocus rates ORPOF with a GF Score™ of 41/100 and a GF Value™ of $2.12. The stock has 6 warning signs investors should review. Among 841 Biotechnology companies, OSE Immunotherapeutics ranks worse than 93.82% on this metric.
OSE Immunotherapeutics (OTCPK:ORPOF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
OSE Immunotherapeutics Days Sales Outstanding Related Terms
OSE Immunotherapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for OSE Immunotherapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSE Immunotherapeutics Days Sales Outstanding Chart
ORPOF vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, OSE Immunotherapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OSE Immunotherapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where OSE Immunotherapeutics's Days Sales Outstanding falls into.
OSE Immunotherapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 315.83 mean?
OSE Immunotherapeutics (ORPOF) has a Days Sales Outstanding of 315.83 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on OSE Immunotherapeutics and its competitors. This is 1092% above median its historical median of 26.50. Over the past decade, OSE Immunotherapeutics' Days Sales Outstanding has ranged from 11.72 to 11,739.09. According to the industry distribution chart, OSE Immunotherapeutics ranks #789 out of 841 companies in the Biotechnology industry, placing it in the top 93.8%.
Is OSE Immunotherapeutics' Days Sales Outstanding too high?
OSE Immunotherapeutics' current Days Sales Outstanding of 315.83 is 1092% above median its 10-year median of 26.50. Over the past 10 years, this metric has ranged from a low of 11.72 to a high of 11,739.09. The Biotechnology industry median Days Sales Outstanding is 68.94. OSE Immunotherapeutics' value of 315.83 is 358.1% above this industry median. Based on the distribution chart, OSE Immunotherapeutics ranks #789 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OSE Immunotherapeutics has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OSE Immunotherapeutics ranks #789 out of 841 companies for Days Sales Outstanding. This places OSE Immunotherapeutics in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. OSE Immunotherapeutics' value of 315.83 is 358.1% above this benchmark. Historically, OSE Immunotherapeutics' own Days Sales Outstanding has ranged from 11.72 to 11,739.09 over the past decade. While the company's 10-year median is 26.50 vs. the industry median of 68.94, OSE Immunotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OSE Immunotherapeutics's current Days Sales Outstanding of 315.83 is 358.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on OSE Immunotherapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OSE Immunotherapeutics's current Days Sales Outstanding is 315.83, which is 1092% above median its own 10-year median of 26.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
OSE Immunotherapeutics (ORPOF) has a current Days Sales Outstanding of 315.83. The stock's GF Value™ is $2.12, compared to a current price of $4.43 — trading 109% above its estimated fair value. The current Days Sales Outstanding is 315.83, which is 1092% above median its 10-year median of 26.50 and 358.1% above the Biotechnology industry median of 68.94. OSE Immunotherapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current Days Sales Outstanding is 315.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?
Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued.
The current stock price of $4.43 is trading 109% above its estimated GF Value™ of $2.12.
Key valuation signals for ORPOF:
Days Sales Outstanding: 315.83 (1092% above median its 10-year median of 26.50)
GF Value™: $2.12 vs. price of $4.43 (109% above fair value)
Industry Position: 358.1% above the Biotechnology median (#789 of 841)
No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
41GF Score
Get the complete analysis for ORPOF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORPOF has been successfully added to your 
